# **Technical Appendix**

#### **Branching Process Transmission Model**

We created a branching process model to simulate the transmission of marburgvirus disease (MVD), following a similar method to that in (1). Secondary cases were generated from a Poisson distribution, whose mean was the force of infection calculated at any given point in time. Hence, given an epidemiological curve at timestep *t*, the number of cases at (t + 1) is:  $y_t \sim Poisson(\lambda_t)$ 

with

$$\lambda_t = R \Sigma_{s \le t} y_s w(t - s)$$


where R is the reproduction number, and w(.) the probability mass function from the discretised serial interval distribution.

The rate of zoonotic introductions were also Poisson distributed, with mean equal to the rate of introduction observed in data from previous MVD outbreaks. Each case was also categorised as being reported or unreported; reported cases reduced the basic reproduction number,  $R_{basic}$ , by the *intervention efficacy*, IE, a number that incorporates the effects of contact tracing and case isolation. Thus:

$$\begin{split} R_{Unreported} &= R_{basic} \\ R_{Reported} &= R_{basic} (1 - IE) \end{split}$$

Using an Approximate Bayesian Computation (ABC) approach, we obtained the posterior distribution of  $[R_{basic}, IE]$  pairs for each previous outbreak. 100 of these pooled posteriors were randomly drawn and used to simulate 3 vaccination strategies: ring, targeted and mass vaccination, as well as a combination of these.

## **Vaccine Efficacy**



**Figure A1:** Curve showing vaccine efficacy as a logistic function of days after vaccination

Vaccine efficacy (VE) was modelled as a function of the elapsed time (t) between the vaccination and infection of any case. Specifically, we chose a logistic model of the form:

$$VE(t) = \frac{\Phi_1}{1 + \exp(\frac{\Phi_2 - t}{\Phi_3})}$$

where  $\phi_1$  is the maximum vaccine efficacy,  $\phi_2$  the time at which the inflection point of the logistic curve occurs, and  $\phi_3$  the scaling parameter.

From recent results of the VSV-MARV Marburg vaccine (2), the maximal VE,  $VE_{max} \approx 1$  in NHPs. From the same study, the time from vaccination to  $VE_{max}$  was 7 days. We used a nonlinear least squares approach to fit the 2 piecewise functions (the increase in VE from 0 to  $VE_{max}$  and the constant VE once this had been reached).

Hence, VE comprises 3 parts: vaccination delay (where VE = 0), a period when VE gradually increases and, finally, a period of maximal protection. To simplify our model, we assumed VE to be the mean of these values across the duration of a cluster of MVD cases (which was 30 days, according to data from the DRC outbreak).

For prophylactic vaccination strategies, samples of VE are taken from the upper portion of this logistic curve: specifically, we assumed an average of 20 days (s.d. 5 days)

For reactive vaccination strategies, samples of VE are taken from a wider range of the logistic curve (mainly its slope). Specifically, we assumed an average of 9 days (s.d. 4 days) between vaccination and infection.

The reproduction number for individuals who had been vaccinated,  $R_{Vaccinated}$ , (bearing in mind that these people must also have benefitted from other interventions), was:

$$R_{Vaccinated} = R_{basic}(1 - IE)(1 - VE)$$

where:  $R_{basic}$  is the basic reproduction number (before interventions and vaccinations have taken place) and *IE* the intervention efficacy.

# Estimates of the dispersion parameter, k

18 chains (length  $\geq$  1) of transmission were identified in the DRC outbreak.

#### Maximum estimate:

We assume that k = 1 is the upper limit for the dispersion parameter, as this is the value greater than which superspreading events cannot occur.

#### Minimum estimate:

As shown in Table A1, there were 18 putative chains of MVD during the DRC outbreak, of which 16 involved at least two cases. To estimate a minimum value of k, we assumed a scenario where each chain was initiated by a miner who had not been identified as being linked to a chain. We supposed that this occurred even when a suspected primary case had already been identified. Another assumption was that all individuals in each chain were infected directly by the primary case.

Hence, the size of each chain increased by 1 (from the reported size) to  $N_{hypothesised}$ , and the number of secondary cases attributable to each individual in each chain was  $(N_{hypothesised} - 1)$  if they were the primary case, and 0 otherwise.

By fitting to a negative binomial distribution, we estimated that the minimum value of k would therefore be 0.21. This is comparable to the figure of 0.18 seen in the outbreak of Ebola virus in Guinea, 2014 (4).

### Probable estimate:


A more realistic scenario would be to identify the primary case(s) in each cluster. Occasionally, these individuals were signposted in the dataset, but more often we designated either the miner in the chain or the first individual to display MVD symptoms as the primary case.

We also used the knowledge that *"incidences of secondary spread from at least 20 patients, tertiary spread from at least 3 patients, and quaternary spread from at least 2 patients were documented, most often related to the exposure of family members caring for a sick miner"* (5)

Hence, we identified the 2 individuals from whom quaternary spread occurred; these were the index cases in chains G (consisting of 4 individuals) and M (5 individuals). The individuals involved in tertiary spread were those infected by the index cases in chains G and M, as well as the index case of one of the chains with 3 patients. 4 individuals from these chains can then be identified as secondary transmitters. This leaves us with 16 further individuals, belonging to 13 chains, from whom secondary spreading occurred. If a chain contained only 2 individuals, then there must therefore be only 1 index case and 1 secondary infection in that chain. If, however, there were 3 individuals, there could be either 1 or 2 index cases respectively. If there was only 1 index case, then they must infect 2 individuals, whereas if there are 2, only one of them will infect the 3rd. Using such logic, we determined the number of individuals each case infects and, after fitting to a negative binomial distribution, we determined that a more probable estimate of the dispersion parameter was 0.52 < k < 0.67.


## **Serial Interval Distribution**

The serial interval can be modelled as a gamma distribution with a mean of 9.2 days and standard deviation of 4.4 days. Figure A2 shows a plot of observed and fitted values.



**Figure A2:** Plot of fitted and observed values of the serial interval for marburgvirus disease.

Outbreak Location	Year(s)	Probable and Confirmed Cases	Deaths
Marburg, Germany	1967	24	5
Frankfurt, Germany	1967	6	2
Belgrade, Yugoslavia	1967	2	0
Johannesburg, South Africa	1975	3	1
Nairobi, Kenya	1980	2	1
Nairobi, Kenya	1987	1	1
Durba and Watsa, Democratic Republic of Congo	1998-2000	154	128
Uige, Angola	2004-2005	374	329
Uganda	2007	4	2
USA (via Uganda)	2008	1	0
Netherlands (via Uganda)	2008	1	1
Uganda	2012	26	15
Uganda	2014	1	1
Uganda	2017	4	1
Guinea	2021	1	1



**Figure A3:** Scatterplots showing the logarithm (base 10) of the number of marburgvirus cases (confirmed and probable) according to: A. proportion of zoonotic cases, B. days until intervention and C. year of outbreak. Red dots indicate outbreaks affected by civil war (namely, DRC and Angola).

# References

- Jombart T, Jarvis CI, Mesfin S, Tabal N, Mossoko M, Mpia LM, et al. The cost of insecurity: from flare-up to control of a major Ebola virus disease hotspot during the outbreak in the Democratic Republic of the Congo, 2019. Eurosurveillance. 2020 Jan 16;25(2):1900735.
- Marzi A, Jankeel A, Menicucci AR, Callison J, O'Donnell KL, Feldmann F, et al. Single Dose of a VSV-Based Vaccine Rapidly Protects Macaques From Marburg Virus Disease. Front Immunol [Internet]. 2021 [cited 2022 Mar 11];12. Available from: https://www.frontiersin.org/article/10.3389/fimmu.2021.774026
- Masterson SG, Lobel L, Carroll MW, Wass MN, Michaelis M. Herd Immunity to Ebolaviruses Is Not a Realistic Target for Current Vaccination Strategies. Front Immunol [Internet]. 2018 [cited 2022 Mar 23];9. Available from: https://www.frontiersin.org/article/10.3389/fimmu.2018.01025
- 4. Althaus CL. Ebola superspreading. Lancet Infect Dis. 2015 May 1;15(5):507–8.
- Bausch DG, Nichol ST, Muyembe-Tamfum JJ, Borchert M, Rollin PE, Sleurs H, et al. Marburg Hemorrhagic Fever Associated with Multiple Genetic Lineages of Virus. N Engl J Med. 2006 Aug 31;355(9):909–19.